rosiglitazone has been researched along with Liver Neoplasms in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.70) | 18.2507 |
| 2000's | 12 (44.44) | 29.6817 |
| 2010's | 13 (48.15) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Carbonara, G; Fracchiolla, G; Laghezza, A; Lavecchia, A; Loiodice, F; Novellino, E; Piemontese, L; Tortorella, P; Trisolini, R | 1 |
| Chen, S; Chen, Y; Fu, L; Zhang, L | 1 |
| Chae, YR; Cho, IS; Jang, SY; Kim, GR; Kim, JH; Nam, CM; Yoo, HR | 1 |
| Dansako, H; Gu, W; Kato, N; Nishitsuji, H; Satoh, S; Shimotohno, K; Ueda, Y | 1 |
| Li, J; Liu, L; Liu, Y; Sun, J; Xia, S; Xu, D; Xu, Y; Yang, Z; Zhang, L; Zou, F | 1 |
| Herrigel, DJ; Moss, RA | 1 |
| Cao, LQ; Jiang, XF; Liang, HH; Shao, ZL; Xue, P; Yang, XW; Zhang, DW | 1 |
| Chang, YF; Chen, HC; Chi, CW; Hsia, CY; Hsu, HT; Lee, HC; Weng, JW | 1 |
| Cao, LQ; Chen, JS; Chen, XL; Fu, XH; Huang, XH; Jiao, XY; Lu, HW; Peng, HP; Wang, Q; Wang, XL; Xue, P; Zheng, Q | 1 |
| Liang, ZQ; Peng, L; Xu, Z; Yang, T; Zhang, M; Zhou, Y | 1 |
| Cao, LQ; Peng, HP; Shao, ZL; Xia, T; Xiao, JB | 1 |
| Crabb, DW; Liangpunsakul, S; Lu, C; Sozio, MS; Zeng, Y | 1 |
| Cheng, JT; Chu, ES; Farrell, GC; Li, G; Lo, CM; Man, K; Nie, Y; Shen, B; Sung, JJ; Teoh, N; Wu, CW; Yu, J; Zhao, G | 1 |
| Davaa, E; Park, JS | 1 |
| Chan, DS; Chan, EC; Chui, WK; Ho, HK; Lee, CY; New, LS; Saha, S; Wong, W; Yap, CW | 1 |
| Cheng, AS; Cheung, KF; Hao, Y; Li, X; Lowe, AW; Sung, JJ; Yu, J; Zhao, J | 1 |
| Bae, MA; Rhee, H; Song, BJ | 1 |
| Ehrenborg, E; Hall, K; Hilding, A; Lewitt, MS; Skogsberg, J | 1 |
| Katoh, M; Maniratanachote, R; Minami, K; Nakajima, M; Yokoi, T | 1 |
| Guo, YT; Leng, XS; Li, T; Lin, XH; Zhao, JM | 1 |
| Borkan, SC; Matsuhashi, N; Nakajima, A; Ohnishi, S; Saubermann, LJ; Schaefer, KL; Takahashi, H; Turner, JR; Wada, K; Wolfe, MM | 1 |
| Jin, J; Li, Z; Wang, L; Wu, N; Zha, XL; Zhang, W | 1 |
| Blann, E; Dial, S; Dragan, YP; Guo, L; Muskhelishvili, L; Schroth, G; Shi, L; Sun, Y; Zhang, L | 1 |
| Gao, L; Hong, B; Jiang, W; Si, S; Wang, M; Yang, Y; Zhang, Z; Zhao, G; Zheng, Z | 1 |
| Bi, J; Cao, LQ; Chen, XL; Huang, XH; Li, W; Wang, Q; Zhang, LJ; Zhen, MC | 1 |
| Baek, HA; Choi, HN; Chung, MJ; Jang, KY; Kim, KR; Lee, HJ; Moon, WS; Park, HS | 1 |
| Baugé, E; Chinetti, G; Clavey, V; Copin, C; Dallongeville, J; Fruchart, J; Fruchart, JC; Mariotte, MC; Staels, B | 1 |
2 review(s) available for rosiglitazone and Liver Neoplasms
| Article | Year |
|---|---|
Inhibiting Sodium Taurocholate Cotransporting Polypeptide in HBV-Related Diseases: From Biological Function to Therapeutic Potential.
Topics: Carcinoma, Hepatocellular; Hep G2 Cells; Hepatitis B; Hepatitis B virus; Hepatocytes; Humans; Interferons; Liver Neoplasms; Nucleotides; Organic Anion Transporters, Sodium-Dependent; Symporters; Virus Internalization | 2022 |
Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Complications; Humans; Hypoglycemic Agents; Insulin; Liver Neoplasms; Metformin; Non-alcoholic Fatty Liver Disease; Pancreatic Neoplasms; Pioglitazone; Precancerous Conditions; Receptors, Somatomedin; Risk Factors; Rosiglitazone; Thiazolidinediones | 2014 |
25 other study(ies) available for rosiglitazone and Liver Neoplasms
| Article | Year |
|---|---|
Synthesis, biological evaluation, and molecular modeling investigation of chiral 2-(4-chloro-phenoxy)-3-phenyl-propanoic acid derivatives with PPARalpha and PPARgamma agonist activity.
Topics: Binding Sites; Cell Line, Tumor; Computer Simulation; Hepatoblastoma; Humans; Liver Neoplasms; Models, Molecular; Molecular Structure; PPAR alpha; PPAR gamma; Propionates; Structure-Activity Relationship; Thermodynamics | 2008 |
Statistical methods for elimination of guarantee-time bias in cohort studies: a simulation study.
Topics: Algorithms; Bias; Carcinoma, Hepatocellular; Cohort Studies; Computer Simulation; Humans; Hypoglycemic Agents; Liver Neoplasms; Models, Statistical; Proportional Hazards Models; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors | 2017 |
A new hepatoma cell line exhibiting high susceptibility to hepatitis B virus infection.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclosporine; Hep G2 Cells; Hepatitis B; Hepatitis B virus; Host-Pathogen Interactions; Humans; Liver Neoplasms; Organic Anion Transporters, Sodium-Dependent; Rosiglitazone; Symporters; Virus Internalization | 2019 |
Inhibition of oxidative stress-elicited AKT activation facilitates PPARγ agonist-mediated inhibition of stem cell character and tumor growth of liver cancer cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Glycoproteins; Humans; Liver Neoplasms; Male; Membrane Glycoproteins; Mice; Mice, Nude; NADPH Oxidase 2; NADPH Oxidases; Neoplastic Stem Cells; Oxidative Stress; Peptides; Phenotype; PPAR gamma; Prostaglandin D2; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Ribonucleosides; Rosiglitazone; Thiazolidinediones | 2013 |
Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits hepatoma cell growth via downregulation of SEPT2 expression.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Caspase 9; Cell Movement; Cell Proliferation; Computational Biology; Down-Regulation; Electrophoresis, Gel, Two-Dimensional; Hep G2 Cells; Humans; Liver Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; PPAR gamma; Proteomics; RNA Interference; Rosiglitazone; Septins; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Thiazolidinediones; Transfection | 2015 |
Combined effect of honokiol and rosiglitazone on cell growth inhibition through enhanced G0/G1 phase arrest in hepatoma cells.
Topics: Antineoplastic Agents, Phytogenic; Biphenyl Compounds; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; G1 Phase Cell Cycle Checkpoints; Humans; Lignans; Liver Neoplasms; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2016 |
Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cyclooxygenase 2; Down-Regulation; Drug Resistance, Neoplasm; Fluorouracil; Humans; Liver Neoplasms; PPAR alpha; PTEN Phosphohydrolase; Rosiglitazone; Thiazolidinediones; Transcriptional Activation; Tumor Cells, Cultured | 2009 |
[Effect of rosiglitazone on cells cycle, apoptosis and expression of Skp2 and p27Kip1 in hepatocellular carcinoma cell line].
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; PTEN Phosphohydrolase; Rosiglitazone; S-Phase Kinase-Associated Proteins; Thiazolidinediones | 2010 |
Rosiglitazone enhances 5-fluorouracil-induced cell growth inhibition in hepatocellular carcinoma cell line Hep3B.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Fluorouracil; Gene Silencing; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; PPAR gamma; PTEN Phosphohydrolase; RNA, Small Interfering; Rosiglitazone; Signal Transduction; Thiazolidinediones; Tumor Burden | 2010 |
Activated AMPK inhibits PPAR-{alpha} and PPAR-{gamma} transcriptional activity in hepatoma cells.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Liver Neoplasms; Metformin; PPAR alpha; PPAR gamma; Rats; Ribonucleosides; Rosiglitazone; Thiazolidinediones; Transcriptional Activation | 2011 |
PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice.
Topics: Animals; Biomarkers, Tumor; Blotting, Western; Cadherins; Carcinoma, Hepatocellular; Cell Adhesion; Cell Movement; Chromatin Immunoprecipitation; Gene Expression Profiling; Humans; Hypoglycemic Agents; In Vitro Techniques; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oligonucleotide Array Sequence Analysis; PPAR gamma; Real-Time Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Tumor Cells, Cultured | 2012 |
Formulation parameters influencing the physicochemical characteristics of rosiglitazone-loaded cationic lipid emulsion.
Topics: Biological Transport; Carcinoma, Hepatocellular; Castor Oil; Cations; Chemistry, Pharmaceutical; Drug Carriers; Drug Stability; Emulsions; Fatty Acids, Monounsaturated; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Hypoglycemic Agents; Insulin Resistance; Lipids; Liver Neoplasms; Nanoparticles; Particle Size; Phosphatidylethanolamines; Polysorbates; Quaternary Ammonium Compounds; Rosiglitazone; Solubility; Surface-Active Agents; Technology, Pharmaceutical; Thiazolidinediones | 2012 |
Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer properties.
Topics: 3T3-L1 Cells; Animals; Antineoplastic Agents; Biotransformation; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromans; Dose-Response Relationship, Drug; Drug Design; Fatty Acid-Binding Proteins; Gene Expression Regulation; Glutathione; Humans; Hypoglycemic Agents; Liver Neoplasms; Mice; Microsomes, Liver; Molecular Structure; Phosphorylation; Pioglitazone; PPAR gamma; Protein Carbonylation; Receptor Protein-Tyrosine Kinases; Receptors, Peptide; Rosiglitazone; Structure-Activity Relationship; Succinimides; Thiazolidinediones; Troglitazone | 2012 |
CITED2 is a novel direct effector of peroxisome proliferator-activated receptor γ in suppressing hepatocellular carcinoma cell growth.
Topics: Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Down-Regulation; Gene Knockdown Techniques; Humans; Liver Neoplasms; PPAR gamma; Repressor Proteins; Rosiglitazone; Thiazolidinediones; Trans-Activators; Transfection | 2013 |
Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines.
Topics: Animals; Antineoplastic Agents; Apoptosis; CDC2-CDC28 Kinases; Cell Cycle; Cell Cycle Proteins; Chromans; Cyclin A; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; G1 Phase; Humans; Liver Neoplasms; Protein Serine-Threonine Kinases; Rats; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2003 |
Troglitazone stimulates IGF-binding protein-1 by a PPAR gamma-independent mechanism.
Topics: Carcinoma, Hepatocellular; Chromans; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor Binding Protein 1; Kinetics; Liver Neoplasms; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone; Tumor Cells, Cultured | 2003 |
Chaperone proteins involved in troglitazone-induced toxicity in human hepatoma cell lines.
Topics: Amino Acid Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Chromans; Dose-Response Relationship, Drug; Endoplasmic Reticulum Chaperone BiP; Gene Expression Regulation; Heat-Shock Proteins; Humans; Hypoglycemic Agents; Liver Neoplasms; Molecular Chaperones; Molecular Sequence Data; Protein Disulfide-Isomerases; Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Messenger; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; Transfection; Troglitazone | 2005 |
Peroxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats.
Topics: Alkylating Agents; Animals; Anticarcinogenic Agents; Chromans; Diethylnitrosamine; Gene Expression; Glutathione Transferase; Hypoglycemic Agents; Immunohistochemistry; Ligands; Liver Neoplasms; Male; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Troglitazone | 2004 |
Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells.
Topics: Anilides; Anoikis; Benzamides; Carcinoma, Hepatocellular; Cell Adhesion; Cell Growth Processes; Cell Line, Tumor; Cell Shape; Chromans; Extracellular Matrix; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Humans; Integrin beta1; Liver Neoplasms; PPAR gamma; Protein-Tyrosine Kinases; Pyridines; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
PPARgamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404.
Topics: Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Focal Adhesion Kinase 1; Humans; Hypoglycemic Agents; Immunoblotting; Liver Neoplasms; Luciferases; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; PPAR gamma; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazolidinediones; Tumor Cells, Cultured; Up-Regulation | 2006 |
Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells.
Topics: Animals; Carcinoma, Hepatocellular; Cells, Cultured; Chromans; Cluster Analysis; Gene Expression Profiling; Gene Expression Regulation; Hepatocytes; Humans; Hypoglycemic Agents; Liver Neoplasms; Pioglitazone; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Transcription, Genetic; Troglitazone | 2006 |
Identification of novel human high-density lipoprotein receptor Up-regulators using a cell-based high-throughput screening assay.
Topics: Actinomycetaceae; Biological Assay; Carbocyanines; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fermentation; Fluorescent Dyes; Gene Expression Regulation; Genes, Reporter; Humans; Hydroxyl Radical; Isoflavones; Lipoproteins, HDL; Liver Neoplasms; Luciferases; PPAR gamma; Receptors, Lipoprotein; Recombinant Fusion Proteins; Rosiglitazone; Scavenger Receptors, Class B; Thiazolidinediones; Transcription, Genetic; Up-Regulation | 2007 |
Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line; Humans; Hypoglycemic Agents; Liver Neoplasms; Phosphatidylinositol 3-Kinases; PPAR gamma; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Rosiglitazone; Signal Transduction; Thiazolidinediones; Up-Regulation | 2007 |
A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
Topics: Anilides; Benzamides; Blotting, Western; Carcinoma, Hepatocellular; Cell Adhesion; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Chromans; Colony-Forming Units Assay; Humans; Hypoglycemic Agents; Immunoenzyme Techniques; Ligands; Liver Neoplasms; Neoplasm Invasiveness; PPAR gamma; Pyridines; Rosiglitazone; Thiazolidinediones; Troglitazone; Vimentin | 2007 |
Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins C; Blood; Carcinoma, Hepatocellular; Cattle; Culture Media; DNA-Binding Proteins; Fenofibrate; Gemfibrozil; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Kinetics; Liver Neoplasms; Pyrimidines; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured | 1999 |